Biography:
Roberto Gramignoli has been working as a Senior Researcher and Group Leader at Karolinska Institutet, and recently appointed as Head of Division for Cell Therapies at Gaslini Hospital in Italy. He is specialized in Medical Genetics and advanced medicinal products, in addition to a PhD in Molecular and Translational Medicine. During his post-graduate studies at Univ. of Pittsburgh (PA-USA) he identified and proposed new solutions for roadblocks limiting clinical Hepatocyte Transplantation. Due to the paucity of human hepatocytes, he investigated alternative sources, such as iPS and placental stem cells. Working with his Mentor, Dr Strom, they became the first group to get approval for isolation and clinical infusion of human hepatocytes and amnion epithelial stem cells (AEC).
Over the past years, he has accumulated evidence on the potential of AEC in several models of congenital liver diseases and as supporting therapy in fulminant hepatic failure. Based on safety and efficacy, in addition to AEC immunomodulatory and anti-inflammatory effects, they are in the process of starting a phase I/IIa clinical trial for liver disease and creating the first placenta stem cell bank.
Title : Amniotic epithelial cells and released mediators in support of regenerative effects, oncological treatments, and immune acceptance in allogeneic settings
Title : Humanized chimeric animals to test drugs or evaluate novel cell and gene therapies
Title : Cellular Mechanism in support of perinatal Amnion Epithelial Stem Cell Transplantation without Immunosuppression